MedX Health Corp. Confirms Details of Closings of Non-Brokered Private Placements

May 20, 2020 (Source) – MedX Health Corp. (“MedX” or the “Company”) (TSX-V: MDX) confirms the precise specifics of the series of closings of non-brokered private placements made since January 30, 2020, announced in recent Press Releases by the Company. The following Table sets out the particulars of the dates of each closing, the number of units issued and the amount raised on each closing, together with details of Agent’s Warrants and cash commissions paid to Agents at each closing.






January 30, 2020





March 4, 2020





March 5, 2020





April 22, 2020





April 27, 2020





April 29, 2020





May 13, 2020










Each Unit (“Unit”) was issued at the price of $0.12, and comprises one fully paid common share and one share purchase warrant, exercisable at $0.20 for a period expiring on the second anniversary of each respective issue; all the securities issued are restricted from trading for a period of four months from their respective dates of issue. Included in the securities issued on April 27, 2020, are 200,000 units, at a total cost of $24,000, subscribed for by an Insider. Final Acceptance has been obtained from the TSX-V in relation to the closings which took place on January 30, March 4 and March 5, 2020, while the closings which took place on April 22, 27 and 29, and May 13, 2020, which are part of the proposed private placement announced in the Company’s Press Release dated March 6, 2020, are still subject to Final Acceptance from the TSX-V.

Each Agent’s Warrant, which is non-transferable, is exercisable to acquire one Unit at $0.12 per Unit, at any time during the period of two years following the respective dates of issue.

The funding from these placements will be used by MedX for further development and enhancement of its telemedicine software platform, marketing initiatives and general corporate purposes, including adding additional resources while it expands into new markets, in particular in Latin America and the USA where the Company is anticipating rapid growth.

About MedX

MedX, headquartered in Mississauga, Ontario, is a leading medical device and software company focused on skin cancer with its DermSecure™ telemedicine platform, utilizing its SIAscopy technology. SIAscopy is also imbedded in its products SIAMETRICS™, SIMSYS™, and MoleMate™, which MedX manufactures in its ISO 13485 certified facility. SIAMETRICS™, SIMSYS™, and MoleMate™ include hand-held devices that use patented technology utilizing light and its remittance to view up to 2 mm beneath suspicious moles and lesions in a pain free, non-invasive manner, with its software then creating real-time images for physicians and dermatologists to evaluate all types of moles or lesions within seconds. These products are Health Canada, FDA (US), ARTG and CE cleared for use in Canada, the US, Australia, New Zealand, the European Union and Turkey. MedX also designs, manufactures and distributes quality photobiomodulation therapeutic and dental lasers to provide drug-free and non-invasive treatment of tissue damage and pain. www.medxhealth.com.

This press release does not constitute an offer of any securities for sale. This press release contains certain forward-looking statements within the meaning of applicable Canadian securities legislation. These forward-looking statements involve certain risks and uncertainties that could cause actual results to differ, including, without limitation, the company’s limited operating history and history of losses, the inability to successfully obtain further funding, the inability to raise capital on terms acceptable to the company, the inability to compete effectively in the marketplace, the inability to complete the proposed acquisition and such other risks that could cause the actual results to differ materially from those contained in the company’s projections or forward-looking statements. All forward looking statements in this press release are based on information available to the company as of the date hereof, and the company undertakes no obligation to update forward-looking statements to reflect events or circumstances occurring after the date of this press release.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.